Related Experiment Video

Updated: May 31, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Ifosfamide nephropathy in patients with sarcoma

Mohammad Ali Mashhadi1, Houshang Sanadgol, Mahmoudali Keikhaei

  • 1Department of Hematology and Oncology, Zahedan University of Medical Sciences, Zahedan, Iran. dralimashhadi@yahoo.com

Iranian Journal of Kidney Diseases
|July 5, 2011
PubMed
Abstract

Insights

Ifosfamide chemotherapy can cause kidney damage (nephropathy) in sarcoma patients. This study found varying degrees of ifosfamide nephropathy, highlighting the need for revised monitoring strategies.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Ifosfamide is a key alkylating agent for sarcoma treatment.
  • Major ifosfamide toxicities include nephropathy, neuropathy, and hematologic complications.
  • This study focuses on ifosfamide-induced nephropathy in sarcoma patients.

Purpose of the Study:

  • To determine the frequency and severity of ifosfamide nephropathy.
  • To analyze renal side effects in patients receiving ifosfamide for sarcoma.

Main Methods:

  • Ninety sarcoma patients (52 male, 38 female) treated with ifosfamide were analyzed.
  • Data included physical exams, lab results, and glomerular filtration rate.
  • Follow-up duration ranged from 6 to 12 months.

Main Results:

  • Renal side effects observed: proteinuria (15.5%), microscopic hematuria (14.4%), glycosuria (7.8%), and elevated serum creatinine (2.2%).
  • A combination of proteinuria and glycosuria occurred in 5.5% of patients.
  • No gross hematuria was reported, but microscopic hematuria was present in 14.4%.

Conclusions:

  • Ifosfamide nephropathy presents with varying severity in sarcoma patients.
  • Current monitoring protocols for ifosfamide side effects may require adjustments for different patient populations.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...